Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

Inclusion Criteria

• •Patients must have cHL that has not been previously treated
• •* Part A: Any stage
• •* Part B: Must be stage 3 or 4
• •Patients must be appropriate candidates for at least 2 cycles of doxorubicin hydrochloride (adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) (6 cycles for Part B patients) or doxorubicin hydrochloride, vinblastine, dacarbazine (AVD) (this could include patients ranging from favorable risk early stage disease to poor prognosis advanced stage disease)
• •Patients must have measurable FDG-avid disease defined by standard criteria (Lugano 2014) and a minimum of 1.0 cm in diameter
• •Patients should not have evidence of active central nervous system lymphoma
• •Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• •Patients must have a left ventricular ejection (LVEF) \>= 50% within 56 days of enrollment
• •Patients must have adequate labs within 10 days of treatment
• •Absolute neutrophil count (ANC) \>= 1,500/mm\^3 (without transfusion or growth factor support)
• •Platelets \>= 100,000/mm\^3 (without transfusion or growth factor support)
• •Hemoglobin \>= 8 g/dL. Growth factor and/or transfusion support is permissible to stabilize participant prior to study treatment if needed. There is no lower limit to cytopenias if related to bone marrow involvement
• •Serum creatinine \< 1.5 mg/dl or creatinine clearance greater than 30/ml per minute by Cockcroft Gault formula
• •Total bilirubin =\< 1.5 times upper limit of normal OR direct bilirubin =\< upper limit of normal (ULN) for participants with total bilirubin levels \> 1.5 x ULN
• •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 times upper limit of normal (=\< 5 x ULN for participants with liver metastases)
• •All patients must be informed of the investigational nature of this study and have given written consent in accordance with institutional and federal guidelines
• •Patients must be anticipated to complete all planned study therapy
• •Male subjects should agree to use an adequate method of barrier contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy
• •Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
• •Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \> 1 year